Inspire Medical Systems (NYSE:INSP) Updates FY 2025 Earnings Guidance

Key Points

• Inspire Medical Systems updated its FY 2025 earnings guidance, projecting earnings per share between 0.400-0.500, significantly lower than the consensus estimate of 0.960.
• The company also provided revenue guidance of $900.0 million-$910.0 million, slightly above the consensus estimate of $904.5 million.
• Inspire's CFO recently sold 11,000 shares at an average price of $93.39, indicating a 19.69% decrease in ownership of the stock.

Inspire Medical Systems (NYSE:INSP - Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 0.400-0.500 for the period, compared to the consensus earnings per share estimate of 0.960. The company issued revenue guidance of $900.0 million-$910.0 million, compared to the consensus revenue estimate of $904.5 million.

Inspire Medical Systems Stock Performance

Shares of INSP opened at $78.96 on Tuesday. The firm has a market capitalization of $2.33 billion, a price-to-earnings ratio of 45.64, a price-to-earnings-growth ratio of 2.49 and a beta of 1.15. Inspire Medical Systems has a one year low of $73.92 and a one year high of $218.52. The stock's fifty day moving average is $98.63 and its 200-day moving average is $129.96.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported $0.45 EPS for the quarter, beating analysts' consensus estimates of $0.22 by $0.23. The company had revenue of $217.09 million for the quarter, compared to analyst estimates of $214.50 million. Inspire Medical Systems had a return on equity of 10.38% and a net margin of 6.17%.The company's quarterly revenue was up 10.8% compared to the same quarter last year. During the same period last year, the company earned $0.32 earnings per share. Inspire Medical Systems has set its FY 2025 guidance at 0.400-0.500 EPS. Analysts forecast that Inspire Medical Systems will post 2.16 EPS for the current fiscal year.

Inspire Medical Systems declared that its board has initiated a share repurchase program on Monday, August 11th that permits the company to buyback $200.00 million in outstanding shares. This buyback authorization permits the company to repurchase up to 8.6% of its shares through open market purchases. Shares buyback programs are usually an indication that the company's leadership believes its shares are undervalued.

Analyst Upgrades and Downgrades

INSP has been the topic of a number of analyst reports. KeyCorp cut Inspire Medical Systems from an "overweight" rating to a "sector weight" rating in a research note on Tuesday, August 5th. JPMorgan Chase & Co. cut Inspire Medical Systems from an "overweight" rating to a "neutral" rating and dropped their price target for the stock from $195.00 to $110.00 in a research note on Tuesday, August 5th. Royal Bank Of Canada dropped their price target on Inspire Medical Systems from $215.00 to $180.00 and set an "outperform" rating on the stock in a research note on Tuesday, August 5th. Evercore ISI started coverage on Inspire Medical Systems in a research note on Tuesday, September 2nd. They issued an "outperform" rating and a $150.00 price target on the stock. Finally, Wall Street Zen cut Inspire Medical Systems from a "buy" rating to a "hold" rating in a research note on Saturday, July 26th. Seven equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $154.43.

Insiders Place Their Bets

In other news, CFO Richard Buchholz sold 11,000 shares of the stock in a transaction on Friday, August 29th. The stock was sold at an average price of $93.39, for a total transaction of $1,027,290.00. Following the sale, the chief financial officer owned 44,867 shares in the company, valued at approximately $4,190,129.13. This represents a 19.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 2.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Inspire Medical Systems

Several hedge funds have recently added to or reduced their stakes in the stock. Royal Bank of Canada grew its holdings in shares of Inspire Medical Systems by 16.0% during the first quarter. Royal Bank of Canada now owns 32,769 shares of the company's stock worth $5,220,000 after buying an additional 4,528 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new stake in Inspire Medical Systems during the 1st quarter worth approximately $524,000. Goldman Sachs Group Inc. raised its holdings in Inspire Medical Systems by 57.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 51,422 shares of the company's stock valued at $8,190,000 after acquiring an additional 18,857 shares in the last quarter. Marshall Wace LLP raised its holdings in Inspire Medical Systems by 3.8% in the 2nd quarter. Marshall Wace LLP now owns 15,905 shares of the company's stock valued at $2,064,000 after acquiring an additional 577 shares in the last quarter. Finally, Jump Financial LLC bought a new position in shares of Inspire Medical Systems in the 2nd quarter valued at $931,000. Institutional investors and hedge funds own 94.91% of the company's stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.